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Abstract 
Introduction: Controversial data exist in the literature regarding relationship of IL-6 with gestational diabetes mellitus (GDM), partially 
resulting from different criteria for GDM classification. In the present study, we revised this linkage by investigating leukocyte IL6 expres-
sion and its associations with clinical characteristics of patients diagnosed by the Polish Diabetes Association (PDA) 2011 and 2014 criteria.
Material and methods: A total of 145 pregnant women underwent 75 g two-hour OGTT, and GDM was diagnosed according to PDA 2011 
criteria (GDM/PDA 2011 group; n = 113) and PDA 2014 criteria (GDM/PDA 2014 group; n = 104). IL6 gene expression was investigated 
in leukocytes of all participants by using real-time PCR method. 
Results: Compared to respective NGT control groups, the GDM/PDA 2011 group exhibited higher FPG, two-hour OGTT, HbA1C and IL6 
expression and lower HDL-C, whereas the GDM/PDA 2014 group had higher FPG, one-hour and two-hour OGTT, HbA1C and HOMA-IR, 
lower QUICKI-IS, and unchanged IL6 expression. 
No differences in metabolic parameters and IL6 expression were found between the two GDM groups. Compared to the NGT/PDA 2011 
group, the NGT/PDA 2014 group had lower one-hour and higher two-hour OGTT and increased IL6 expression. With PDA 2014 criteria, 
IL6 expression correlated positively with two-hour OGTT in both NGT and GDM groups as well as with LDL-C in NGT group, and 
negatively with HDL-C in NGT group. With PDA 2011 criteria, no associations were evident in NGT and GDM groups. Nevertheless, 
significant positive correlation of IL6 mRNA with two-hour OGTT was observed in the entire study group.
Conclusions: Differences in metabolic phenotypes as well as gene expression and correlation data between GDM and NGT groups, categorised 
based on PDA 2011 and 2014 criteria, are related to changes in gestational glucose tolerance status resulting from using PDA 2014 criteria. Moreover, 
our findings support the hypothesis that IL-6 is associated with glucose metabolism during pregnancy.  (Endokrynol Pol 2017; 68 (3): 317–325)
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Streszczenie
Wstęp: W literaturze istnieją kontrowersyjne dane dotyczące związku IL-6 z cukrzycą ciążową (GDM), częściowo wynikające z różnych kry-
teriów jej klasyfikacji. Celem badania było zrewidowanie istnienia tego związku poprzez badanie ekspresji IL6 w leukocytach i jej korelacji 
z charakterystyką kliniczną pacjentek diagnozowanych zgodnie z kryteriami Polskiego Towarzystwa Diabetologicznego (PTD) z 2011 i 2014 roku.
Materiały i metody: 145 ciężarnych poddano 2 godz. OGTT 75 g i GDM diagnozowano zgodnie z zaleceniami PTD z 2011 roku (grupa 
GDM/PDA 2011; n = 113) i PDA z 2014 roku (grupa GDM/PDA 2014; n = 104). Ekspresję IL6 badano w leukocytach wszystkich uczestni-
czek badania z wykorzystaniem qRT-PCR. 
Wyniki: W porównaniu z odpowiednimi grupami kontrolnymi NGT, grupa GDM/PDA 2011 wykazywała wyższe wartości glikemii na 
czczo i w 2 godz. OGTT jak również wyższe poziomy HbA1C i ekspresji IL6 oraz niższe stężenie HDL-C podczas gdy grupa GDM/PTD 
2014 charakteryzowała się wyższymi wartościami glikemii na czczo oraz w 1 i 2 godz. OGTT, wzrostem HbA1C i HOMA-IR jak również 
obniżeniem QUICKI-IS oraz brakiem zmian w ekspresji IL 6. Nie stwierdzono różnic w parametrach metabolicznych i ekspresji IL 6 mię-
dzy dwoma grupami GDM. W porównaniu z grupą NGT/PDA 2011, grupa NGT/PDA 2014 wykazywała niższe wartości glikemii w 1 h 
i wyższe w 2 godz. OGTT oraz podwyższoną ekspresję IL6. Stosując zalecenia PTD 2014 wykazano, że ekspresja IL6 korelowała dodatnio 
z glikemią w 2 godz. OGTT zarówno w grupie NGT, jak i GDM, jak również ze stężeniem LDL-C w grupie NGT oraz ujemnie z HDL-C 
w grupie NGT. Przy zastosowaniu zaleceń PTD 2011, w grupach NGT i GDM nie obserwowano żadnych korelacji. Stwierdzono, istotną 
dodatnią korelację między ekspresją IL6 a glikemią w 2 godz. OGTT w całej badanej populacji.
Wnioski: Różnice w fenotypach metabolicznych jak również w ekspresji genu IL6 i korelacjach między grupami GDM i NGT, podzielonymi zgodnie 
z kryteriami PDA 2011 i 2014, są związane ze zmianami stanu tolerancji glukozy w czasie ciąży wynikającymi z zastosowania kryteriów PDA 2014. 
Uzyskane wyniki potwierdzają także hipotezę, że IL-6 jest związana z metabolizmem glukozy podczas ciąży.  (Endokrynol Pol 2017; 68 (3): 317–325)
Słowa kluczowe: Polskie Towarzystwo Diabetologiczne (PTD); kryteria diagnostyczne, interleukina 6 (IL-6); cukrzyca ciążowa (GDM) 
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Introduction
Gestational Diabetes Mellitus (GDM) is an increasingly 
common complication of pregnancy
characterised by carbohydrate intolerance resulting in 
maternal hyperglycaemia with onset or first recognition 
during pregnancy. GDM is associated with adverse out-
comes for the mother and her offspring [1]. In the long 
term, GDM women are at elevated risk of developing 
type 2 diabetes (T2DM), cardiovascular diseases, and 
metabolic syndrome at a later age [2–4]. Additionally, 
children born with pregnancy complicated by GDM 
are at increased risk for the development of obesity 
and abnormal glucose metabolism during childhood, 
adolescence, and adulthood [5].
The screening procedures and diagnostic criteria 
for GDM vary between countries and even within 
countries, leading to different estimates of the preva-
lence of GDM, among others. In 1999, the World Health 
Organisation (WHO) introduced the diagnostic criteria 
for GDM based on a two-hour 75 g oral glucose toler-
ance test (OGTT) with fasting plasma glucose (FPG) 
concentration of ≥ 126 mg/dL (7 mmol/L) or two-
hour plasma glucose concentration of ≥ 140 mg/dL 
(7.8 mmol/L) as the cutoff for diagnosis of GDM [6]. 
The Polish Diabetes Association (PDA) recommended 
the use of modified WHO criteria with lowered the 
FPG cutoff to 100 mg/dL (5.6 mmol/L) [7]. In an at-
tempt to unify the GDM criteria throughout the 
world, the International Association of the Diabetes in 
Pregnancy Study Group (IADPSG) proposed in 2010 
new diagnostic criteria for GDM based on the results 
of the Hyperglycaemic Adverse Pregnancy Outcome 
(HAPO) study, which estimated the risk of maternal 
and foetal outcomes related to maternal hyperglycae-
mia [8]. According to the IADPSG guidelines, GDM is 
diagnosed based on a two-hour 75 g OGTT with the 
following thresholds: fasting plasma glucose (FPG) 
≥ 92 mg/dL (5.1 mmol/L), or one-hour glucose con-
centration ≥ 180 mg/dL (10.0 mmol/L), or two-hour 
glucose concentration ≥ 153 mg/dL (8.5 mmol/L) [9]. 
The cutoff values in the new criteria were set to reflect 
an odds ratio of at least 1.75 (compared with the popu-
lation mean) for various adverse foetal outcomes. The 
IADPSG criteria were endorsed by the WHO in 2013 
[10] and PDA in 2014 [11].
Inflammation is a complex process regulated by 
a cascade of cytokines and growth factors that has been 
recognised as one of the factors associated with GDM. 
Among cytokines, interleukin (IL)-6 has drawn much 
attention not only as an immune-modulating molecule 
with important functions in the pathology of several 
inflammation-related diseases such as rheumatoid 
arthritis (RA), but also as the cytokine linked to type 
1 and type 2 diabetes. In this regard, the involvement 
of IL-6 in the regulation of glucose homeostasis and 
metabolism by action on skeletal muscle cells, adipo-
cytes, hepatocytes, and pancreatic β-cells has been 
demonstrated [12]. Interestingly, although IL-6 has 
been largely seen as a pro-inflammatory cytokine, 
recent findings suggest its anti-inflammatory role 
during obesity-associated inflammation and metabolic 
disorders [12]. Despite the fact that the relationship 
of IL-6 with GDM has been increasingly investigated 
in recent years, conflicting findings exist regarding 
its levels in patients with GDM vs. healthy pregnant 
controls. In this respect, a recently performed meta-
analysis of IL-6 levels in patients with and without 
GDM in the 2nd/3rd trimesters has revealed that 
among seven analyzed studies, four have shown 
comparable concentrations of this cytokine in patients 
with and without GDM, and three have reported its 
elevated levels in patients with GDM compared with 
healthy controls [13].
These inconsistencies may be attributed to differ-
ences in diagnostic GDM criteria applied (i.e. WHO, 
National Diabetes Data Group, Canadian Diabetes 
Association, Australian Diabetes in Pregnancy) and/or 
gestational age at sampling and/or type of sample (i.e. 
plasma, serum, culture supernatant).
Since IL-6 is produced by various cells and tissues 
during diabetic pregnancy, including leukocytes, adi-
pocyte tissue, placenta, skeletal muscle, fibroblast, and 
endothelial cells, and it is difficult to segregate their 
significance in IL-6 production during GDM, we have 
undertaken studies on the contribution of IL-6 produc-
tion at its transcriptional level in leukocytes obtained 
from GDM women who were diagnosed by either the 
PDA 2011 or the PDA 2014 criteria. We also evaluated 
the impact of the PDA 2011 and 2014 guidelines on 
correlation analyses done between leukocyte IL6 ex-
pression and the clinical characteristics of patients. In 
this study we used leukocytes because these cells are 
well-known to be engaged in modulating inflammatory 
processes during diabetes and its complications and, 
on the other hand, they are a good alternative for less 
accessible metabolic tissues that are difficult to obtain 
from pregnant women. 
Material and methods
Study design
A total of 145 Caucasian pregnant women were en-
rolled and studied at the Outpatient Diabetological 
Clinic “OmniMed” in Lodz (Poland) from June 2011 to 
November 2013. All pregnant women were routinely 
screened for GDM by a 75-g, two-hour OGTT at 24–28 
weeks’ gestation or later if it was not possible during this 
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period, according to the PDA 2011 and 2014 guidelines 
[7, 11]. Out of all pregnant women recruited, those 
with family history of diabetes in first-degree relatives, 
GDM in a previous pregnancy, diabetes diagnosed 
prior to pregnancy, systemic infection, or taking any 
drugs known to affect carbohydrate metabolism were 
excluded from the study.
All clinical investigations were conducted in accor-
dance with the guidelines of the Declaration of Helsinki 
and were approved by the Bioethics Committee for 
Research on Humans at the Medical University in Lodz 
(No. RNN/154/09/KB). All participants provided written, 
informed consent. 
Anthropometric and biochemical measurements 
The information on maternal age and pre-pregnancy 
weight were collected from medical records. Mater-
nal height and weight were measured by standard 
methods, and body mass index (BMI) was calculated 
by dividing the weight in kilograms by the height in 
metres squared. 
Plasma glucose was measured by the glucose oxi-
dase method, glycated haemoglobin (HbA1C) was as-
sayed by a latex enhanced turbidimetric immunoassay 
using specific monoclonal antibodies, and the C reac-
tive protein (CRP) concentration was determined by 
turbidimetric assay with the use of the cassette COBAS 
INTEGRA C-Reactive Protein (Latex) according to the 
manufacturer’s instructions (Roche Diagnostics GmbH, 
Mannheim, Germany). Lipid profiles, including total 
cholesterol (TC), HDL-cholesterol (HDL-C), LDL-cho-
lesterol (LDL-C), and triglyceride (TG) were determined 
by enzymatic colorimetric methods (Roche Diagnostics 
GmbH, Mannheim, Germany). The biochemical assays 
were carried out with a COBAS INTEGRA analyser 
(Roche, SA). Plasma insulin level was quantified using 
Elecsys insulin assay (Roche Diagnostics GmbH, Man-
nheim, Germany). The homeostasis model assessment 
(HOMA) index was used to calculate insulin resistance 
(HOMA-IR) and beta-cell function (HOMA-B) as fol-
lows [14]:
HOMA-IR = [fasting insulin (µU/mL) × fasting 
glucose (mg/dL)]/405 and,
HOMA-B = [360 × fasting insulin (µU/mL)]/[fasting 
glucose (mg/dL) – 63]
To assess insulin sensitivity, the quantitative insulin 
sensitivity check index (QUICKI-IS) was calculated as 
follows: QUICKI = 1/[log(I0) + log(G0)], where I0 is 
the fasting plasma insulin level (µU/mL) and G0 is the 
fasting blood glucose level (mg/dL) [15].
Leukocyte isolation and RNA extraction 
Leukocytes were isolated from the heparinised venous 
blood of the subjects (10 mL) as previously described 
[16, 17]. Total RNA was extracted from leukocytes using 
Tri Reagent according to the manufacturer’s instruc-
tions (Ambion, United States). RNA concentration was 
quantified using a LAMBDA 25 UV spectrophotometer 
(PerkinElmer, UK), and RNA quality and integrity was 
assessed by the A260/A280 ratio. Samples were kept at 
-80°C until assayed. 
cDNA synthesis and Real-Time Polymerase 
Chain Reaction
Four µg of high-quality total RNA was converted to 
cDNA using RevertAid™ H Minus M-MuLV reverse 
transcriptase kit (Fermentas, Lithuania) according to 
the manufacturer’s recommendations. The cDNA was 
diluted ten-fold, and 2 µL of cDNA was used to per-
form RT-PCR using MaximaTM SYBR Green/ROX qPCR 
Master Mix (2×) (Thermo Scientific, United States) and 
specific primers for IL6 and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) as a housekeeping gene. 
Amplification was carried out on a 7500 Real Time PCR 
System (Applied Biosystems, United States) with initial 
denaturation at 95°C for 10 minutes, followed by 40 
cycles of 95°C for 60 seconds, 60°C for 60 seconds. All 
samples were run in duplicate. Amplification of specific 
transcripts was confirmed by melting curve profiles at 
the end of each PCR. The specificity of the PCR was 
further verified by subjecting the amplification products 
to agarose gel electrophoresis. RNA without reverse 
transcriptase during cDNA synthesis as well as PCR 
reaction using water instead of a template showed no 
amplification. 
The threshold cycle (Ct) of each target product 
was determined, and DCt between target and en-
dogenous GAPDH control was calculated as: DCt 
= Ct(IL6) - Ct(GAPDH). The relative expression of the 
IL6 gene relative to invariant control GAPDH was 
determined using the 2-DCt formula [18]. 
Statistical analysis
The data are expressed as median values with 25–75% 
interquartile range. The distribution of analysed 
biochemical and expression data was checked by the 
Shapiro-Wilk test. Differences between the groups 
studied were compared by the nonparametric Mann-
Whitney U (Wilcoxon) test. The non-parametric Spear-
man’s rank test was used for analysis of correlation 
between variables. Additionally, Pearson’s parametric 
correlation was calculated for leukocyte IL6 expression 
and two-hour plasma OGTT transformed by the root of 
the fourth degree to obtain a normal distribution. Sta-
tistical analyses were carried out using a commercially 
available statistical software package (Statistica version 
12.5, StatSoft, Poland), and statistical significance was 
set at P < 0.05. 
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Results
Subject’s characteristics
A total of 145 Caucasian pregnant women underwent 
screening for GDM, and the number of GDM cases 
identified by the PDA 2011 and 2014 criteria was 113 
(i.e. the GDM/PDA 2011 group) and 104 (i.e. the GDM/
PDA2014 group), respectively. Out of 113 GDM/PDA 
2011 patients, 21 women had the two-hour OGTT 
values between 140 and 153 mg/dL and therefore their 
GDM status was changed to NGT when the PDA 2014 
guidelines were used. Among 32 subjects classified as 
the NGT/PDA 2011 group with the PDA 2011 criteria, 
11 had plasma glucose values higher than cutoff with 
the PDA 2014 criteria at one-hour OGTT, and only one 
case had fasting plasma glucose ≥ 92 mg/dL. Hence, 
12 NGT/PDA2011 women were identified as having 
GDM by the PDA 2014 criteria.
Clinical characteristics of the studied GDM and 
NGT groups are summarised in Table I. The GDM and 
NGT groups were comparable for age and parameters 
of adiposity such as pre- and pregnancy BMI and body 
weight gain (P > 0.05), irrespective of any criteria ap-
plied. Compared to respective NGT control groups, the 
GDM/PDA 2014 women exhibited significantly higher 
glucose concentrations (i.e. fasting, one-hour and two- 
-hour OGTT), HbA1C and HOMA-IR values, and lower 
QUICKI indices whereas the GDM/PDA 2011 women 
Table I. Clinical characteristics of pregnant women diagnosed by the PDA 2011 and 2014 criteria
Tabela I. Charakterystyka kliniczna kobiet ciężarnych diagnozowanych zgodnie z kryteriami PTD z 2011 i 2014 roku
PDA 2011 guidelines PDA 2014 guidelines NGT/
PDA 
2011 
vs. 
2014
GDM/
PDA 
2011 
vs. 
2014
Variables NGT/PDA 2011 
(n = 32)
GDM/PDA 2011 
(n = 113)
P NGT/PDA 2014 
(n = 41)
GDM/PDA 2014
(n = 104)
P P P
Age (years) 28.0 (26.0–34.0) 30.5 (27.0–34.0)  0.447 30.0 (26.0–36.0) 30.0 (27.0–33.0) 0.295 0.270 0.519
Pre-pregnancy BMI  
[kg/m2]
23.7 (21.4–25.5) 24.4 (21.2–27.9) 0.161 23.4 (20.3–25.5) 24.4 (22.0–27.9) 0.871 0.958 0.923
Pregnancy BMI [kg/m2] 27.5 (24.5–29.8) 27.6 (25.0–32.7) 0.210 26.6 (23.5–29.8) 28.3 (25.4–32.3) 0.143 0.842 0.782
Body weight gain [kg] 9.5 (6.0–12.0) 8.0 (6.0–11.3) 0.720 7.3 (5.0–10.0) 9.0 (6.0–12.0) 0.285 0.433 0.592
TC [mg/dL] 241.0 (226.0–
268.1)
243.0 (224.0–
274.0)
0.735 252.0 (227.4–
271.1)
241.0 (220.1–275.0) 0.705 0.955 0.991
TGs [mg/dL] 215.0 (177.0–
268.0)
212.4 (179.3–
271.0)
0.993 206.8 (177.2–
249.4)
217.9 (217.9–179.3) 0.775 0.880 0.912
HDL-C [mg/dL] 78.0 (60.0–88.0) 69.8 (55.7–78.0)  0.046* 75.5 (61.5–85.5) 67.9 (55.0–78.0) 0.103 0.779 0.948
LDL-C [mg/dL] 131.0 (112.0–
157.0)
138.0 (114.0–
153.0)
0.708 135.5 (123.5–
155.0)
136.5 (112.0–155.0) 0.789 0.911 0.990
HbA1c (%) 5.3 (4.9–5.6) 5.4 (5.2–5.7)  0.036* 5.3 (5.0–5.5) 5.4 (5.2–5.7)  0.017* 0.770 0.764
FPG [mg/dL] 77.5 (73.0–84.0) 88.0 (79.0–98.0)  < 
0.001*
79.0 (74.0–84.0) 89.0 (80.0–99.5)  < 
0.001*
0.808 0.594
1 h plasma glucose 
[mg/dL]
174.0 (160.0–
186.0)
180.0 (164.0–
202.0)
0.202 161.5 (149.0–
172.5)
187.0 (171.0–203.0)  < 
0.001*
0.002* 0.110
2 h plasma glucose 
[mg/dL]
122.0 (106.0–
132.0)
156.0 (148.0–
176.5)
 < 
0.001*
139.5 (115.0–
147.0)
158.5 (148.5–178.0)  < 
0.001*
0.003* 0.814
Insulin [µlU/mL] 6.6 (2.2–9.9) 5.4 (3.0–9.8) 0.903 4.5 (1.6–7.1) 6.2 (3.0–11.5) 0.099 0.336 0.572
HOME-IR 1.2 (0.5–2.0) 1.2 (0.6–2.3) 0.667 0.8 (0.3–1.4) 1.3 (0.7–2.7)  0.034* 0.321 0.520
HOME-β 158.1 (62.2–
184.8)
76.8 (54.0–145.9) 0.086 106.4 (40.9–168.4) 90.9 (54.5–184.8) 0.823 0.284 0.621
QUICKI-IS 0.4 (0.3–0.4) 0.4 (0.3–0.4) 0.667 0.4 (0.4–0.5) 0.4 (0.3–0.4)  0.034* 0.321 0.520
CRP [mg/L] 3.7 (2.0–8.7) 3.2 (2.2–5.7) 0.413 3.3 (1.9–6.6) 3.2 (2.2–5.5) 0.747 0.734 0.869
BMI —  body mass index; CRP —  C reactive protein; FPG; fast plasma glucose; HOMA-B —  homeostasis model assessment of B-cell function; HDL-C —  high- 
-density lipoprotein; HOMA-IR —  homeostasis model assessment of insulin resistance; LDL-C —  low-density lipoprotein; QUICKI-IS —  quantitative insulin sensitivity 
check index; TC —  total cholesterol; TGs —  triglycerides. Data are presented as median and 25–75 interquartile range. *P < 0.05 as assessed by the Mann-Whitney 
U test.
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had markedly higher glucose concentrations (i.e. fasting 
and 2 h OGTT) and HbA1C, and lower plasma HDL-C 
concentrations (P < 0.05). When compared the two NGT 
groups in respect to clinical parameters, glucose plasma 
concentrations were significantly lower at 1h and higher 
at 2h OGTT in the NGT/PDA 2014 group than the NGT/ 
/PDA 2011 (P < 0.05). Of note, there were no significant 
differences in clinical parameters between the GDM/ 
/PDA 2011 and GDM/PDA 2014 groups (P > 0.05). 
Leukocyte IL6 gene expression 
To examine IL6 gene expression in peripheral leukocytes 
from GDM patients diagnosed by the PDA 2011 and 
2014 vs. respective NGT controls, quantitative real-
time PCR studies were performed. As can be seen in 
Figure 1, a significant increase in leukocyte IL6 mRNA 
expression with a 2.24-fold up-regulation was detected 
in the GDM/PDA 2011 group compared with the NGT/ 
/PDA 2011 group (P<0.05). Interestingly, there was no 
difference in the leukocyte IL6 mRNA level between the 
GDM/PDA 2014 and NGT/PDA 2014 groups (P > 0.05). 
We compared further leukocyte IL6 gene expression be-
tween the two NGT groups and the two GDM groups. 
As shown in Figure 1, leukocyte IL6 mRNA expression 
was significantly increased (2.08-fold up-regulation) in 
the NGT/PDA 2014 group compared with the NGT/PDA 
2011 group (P < 0.05), whereas it did not significantly 
differ between the two GDM groups (P > 0.05).
Correlation studies
To establish whether leukocyte IL6 expression is asso-
ciated with clinical characteristics of the patients given 
in Table I, correlation analyses were made in the NGT 
and GDM groups, classified according to the PDA 2011 
and 2014 criteria, as well as in the entire study group. 
With the PDA 2014 guidelines, leukocyte IL6 mRNA 
positively correlated with two-hour post-load glucose 
concentration in the NGT/PDA 2014 and GDM/PDA 
2014 groups (Spearman’s r = 0.483, P = 0.001 and 
Spearman’s r = 0.280, P = 0.005, respectively) (Table II). 
Moreover, IL6 gene expression associated positively 
with plasma LDL-C concentration (Spearman’s r = 
0.355, P = 0.050) and negatively with plasma HDL-C 
concentration (Spearman’s r = –0.442, P = 0.013) in 
the NGT/PDA 2014 group. With the PDA 2011 criteria, 
no correlation was evident between leukocyte IL6 
mRNA and any of clinical parameters of patients from 
the NGT/PDA 2011 and GDM/PDA 2011 groups. It 
is noteworthy that significant positive correlation of 
leukocyte IL6 gene expression with two-hour post-load 
glucose concentration (Spearman’s r = 0.293, P < 0.001 
and Pearson’s r = 0.302, P < 0.001) was observed in the 
entire study group (Table II and Fig. 2).
Discussion
Despite GDM being a common metabolic disease of 
pregnancy that shares many features of T2DM, in-
cluding glucose intolerance and insulin resistance, its 
screening and diagnosis have been controversial over 
the last three decades, resulting in many inconsisten-
cies in findings obtained from research, clinical, and 
population studies. To standardise the diagnosis of 
GDM, the IADPSG recommended in 2010 universal 
screening of all pregnant women with the 75 g OGTT 
and proposed new blood glucose thresholds for GDM 
diagnosis, which were adopted in 2014 by the PDA 
[9]. Until the end of 2013, the PDA recommended the 
modified WHO criteria for GDM diagnosis [7]. 
The primary goal of this study was to compare 
leukocyte IL6 gene expression in Polish GDM pregnant 
women diagnosed using the PDA 2011 criteria (the 
modified WHO recommendation) and PDA 2014 criteria 
(the same as those the IADPSG guidelines). A total of 145 
pregnant women were included in the present study. 
By applying the PDA 2011 and 2014 criteria, 113 and 
104 pregnant women, respectively, were recognised 
as having GDM. Out of 113 GDM women, 21 had 
a two-hour cut-point between 140 and 153 mg/dL, and 
therefore these cases were classified as NGT by the PDA 
2014 criteria. Thus, it is reasonable to assume that since 
the PDA, like the IADPSG, has increased the two-hour 
cut-point to 153 mg/dL, many cases of GDM might 
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Figure 1. Comparison of IL6 mRNA expression in the NGT and 
GDM groups classified based on the PDA 2011 and PDA 2014 
criteria
Middle line: median; box: interquartile range; whisker: range 
(excluding outliers). *P < 0.05 as assessed by the Mann-Whitney 
U test
Rycina 1. Porównanie ekspresji IL6 mRNA w grupach NGT 
i GDM klasyfikowanych na podstawie kryteriów PTD z 2011 
i 2014 roku
Środkowa linia: mediana; pudełko: zakres międzykwartylowy; 
wąsy: zakres wartości nieodstających. *P < 0,05 jak oszacowano 
przy użyciu testu U Mann-Whitneya
322
PR
A
C
E 
O
RY
G
IN
A
LN
E
Relationship of IL-6 with GDM Katarzyna Mac-Marcjanek et al.
be missed. Interestingly, we also observed that out of 
32 women classified as NGT with the PDA 2011 guide-
lines, 12 were picked up by the PDA 2014 criteria as GDM. 
In the present study, we found that shifting from 
the PDA 2011 criteria to the PDA 2014 guidelines was 
accompanied by changes in metabolic phenotypes of 
GDM patients compared to their respective NGT con-
trols. According to this, the GDM/PDA 2011 patients had 
a higher fasting and two-hour post-load glucose and 
HbA1C levels and lower HDL-C concentration whereas 
the GDM/PDA 2014 patients were characterised by 
a higher fasting, one-hour and two-hour post-load 
glucose, HbA1c, and insulin resistance assessed by the 
HOMA-IR method and lower insulin sensitivity calcu-
lated from the QUICKI equation. The high HOMA-IR 
values and low QUICKI-IS values observed in the GDM 
group are consistent with the findings obtained by 
Endo et al. [19]. Interestingly, no difference was found 
in plasma CRP concentrations between the two GDM 
groups and their respective NGT control groups. CRP is 
a non-specific acute-phase reactant primarily produced 
by the liver in response to inflammatory stimuli and its 
Figure 2. The positive correlation of leukocyte IL6 mRNA 
expression with two-hour OGTT glucose plasma concentration 
in the entire study group of pregnant women (NGT + GDM; 
n = 145) as assessed by the Spearman’s correlation method
Rycina 2. Dodatnia korelacja między ekspresją IL6 mRNA 
w leukocytach a stężeniem glukozy w osoczu w 2 godz. OGTT 
w grupie wszytkich kobiet ciężarnych uczestniczących w badaniu 
(NGT + GDM; n = 145) oszacowana przy użyciu korelacji Spearmana
Table II. The Spearman correlation coefficients between leukocyte IL6 gene expression and clinical parameters of pregnant 
women diagnosed by the PDA 2011 and 2014 criteria
Tabela II. Współczynniki korelacji Spearmana między ekspresją genu IL6 w leukocytach, a klinicznymi parametrami kobiet 
ciężarnych diagnozowanych zgodnie z kryteriami PTD z 2011 i 2014 roku
PDA 2011 guidelines PDA 2014 guidelines
Variables NGT/PDA 2011 GDM/PDA 2011 NGT/PDA 2014 GDM/PDA 2014 All patients  
(NGT + GDM)
r P r P r P r P r P
Age (years) 0.086 0.647 0.106 0.265 0.111 0.489 0.110 0.270 0.108 0.196
Pre-pregnancy BMI [kg/m2] –0.124 0.507 0.076 0.430 0.053 0.747 0.073 0.467 0.068 0.420
Pregnancy BMI [kg/m2] –0.172 0.354 0.114 0.230 < 
–0.001
0.998 0.106 0.286 0.090 0.282
Body weight gain [kg] –0.031 0.870 0.099 0.301 0.059 0.720 0.058 0.565 0.060 0.477
TC [mg/dL] –0.073 0.724 –0.025 0.841 0.079 0.672 –0.118 0.355 –0.045 0.670
TGs [mg/dL] –0.302 0.134 –0.041 0.738 –0.084 0.654 –0.082 0.519 –0.090 0.387
HDL-C [mg/dL] –0.233 0.252 0.031 0.800  –0.442 0.013* 0.027 0.834 –0.107 0.302
LDL-C [mg/dL] 0.084 0.682 0.002 0.988  0.355 0.050* –0.131 0.324 0.051 0.635
HbA1c (%) 0.316 0.101 –0.022 0.821 0.254 0.118 0.010 0.920 0.079 0.353
FPG [mg/dL] 0.045 0.814 –0.129 0.184 0.084 0.611 –0.034 0.737 0.035 0.687
1-h plasma glucose [mg/dL] –0.127 0.546 –0.160 0.141 0.093 0.625 –0.133 0.238 –0.117 0.222
2-h plasma glucose [mg/dL] 0.148 0.427 0.125 0.199  0.483  0.001*  0.280  0.005*  0.293  < 0.001*
Insulin [µlU/ml] –0.285 0.134 –0.043 0.709 –0.183 0.324 –0.057 0.620 –0.073 0.450
HOME-IR –0.193 0.335 0.000 0.997 –0.098 0.613 –0.016 0.892 –0.004 0.968
HOME-β –0.257 0.215 0.048 0.694 –0.052 0.797 –0.066 0.588 –0.079 0.446
QUICKI-IS 0.193 0.335 –0.001 0.997 0.098 0.613 0.016 0.892 0.004 0.968
CRP [mg/L] 0.204 0.287 –0.047 0.681 0.052 0.781 –0.057 0.620 –0.022 0.821
r- and P-values are given. Abbreviations as in Table I. * P < 0.05 GDM vs. NGT
200 2400
OGTT 2h [mg/dL]
r = 0.293
P =  < 0.001
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positive association with GDM was previously reported 
[20, 21]. On the other hand, the effect of maternal obe-
sity on circulating CRP levels was also demonstrated, 
suggesting that obesity can be a major determinant of 
CRP concentration in pregnancy [22]. Therefore, it is 
more likely that the lack of differentiation in plasma 
CRP levels between the GDM and NGT groups found 
in our study, regardless of the diagnostic criteria ap-
plied, could reflect no difference in pre-pregnancy BMI 
between them.
To gain more information about the reasons for the 
above-described metabolic differences by using the 
PDA 2011 and 2014 criteria, a comparison of clinical 
parameters between the two GDM groups and the 
two NGT groups was performed. Although the re-
sults obtained showed a lack of differences in clinical 
parameters between the GDM/PDA 2011 and GDM/
PDA 2014 groups, lower one-hour and higher two-hour 
glucose values were observed in the NGT/PDA 2014 
group vs. the NGT/PDA 2011 group. These findings are 
not entirely surprising given that 21 GDM cases with 
a two-hour cut-point of 140–153 mg/dL shifted from 
the GDM/PDA 2011 group to the NGT/PDA 2014 group 
and 11 NGT cases with one-hour cut-point ≥ 180 mg/dL 
shifted from the NGT/PDA 2011 group to the GDM/
PDA 2014 group. 
It is now well accepted that chronic, low-grade, sys-
temic inflammation, shown by alterations in the concen-
trations of circulating cytokines, is associated with dia-
betes [23]. Among a panel of diabetes-related cytokines, 
IL-6 has drawn much attention as a pleiotropic cytokine 
engaged in metabolic events during T2DM [24], obesity 
[25, 26], and impaired glucose tolerance [27], but its rele-
vance to GDM has been unclear in previous studies [13]. 
Indeed, Kuzmicki et al. [28, 29] observed elevated IL-6 
concentrations in GDM patients compared with normal 
pregnant women, whereas Georgiou et al. [30] did not 
find any difference. Furthermore, a lack of difference in 
IL-6 release from placenta, adipose tissue, and skeletal 
muscle between GDM and NGT women was also ob-
served [31]. By contrast, increased IL6 gene expression 
was detected in subcutaneous fat, but not in placenta of 
GDM women vs. control subjects [32]. The conflicting 
results obtained can in part be attributed to differences 
in GDM diagnostic criteria. Therefore, we renew inter-
est in the connection of IL-6 with GDM in the present 
study by investigating its expression in leukocytes of 
diabetic women diagnosed by either the PDA 2011 or 
2014 guidelines. Our results revealed that compared 
to respective NGT control groups, leukocyte IL6 gene 
expression was significantly increased in the GDM/PDA 
2011 group, but it remained unchanged in the GDM/ 
/PDA 2014 group. When leukocyte IL6 expression was 
compared between the two GDM groups and the two 
NGT groups, there was no change in its level between 
the GDM/PDA 2011 and GDM/PDA 2014 groups, while 
it was markedly increased in the NGT/PDA 2014 group 
vs. the NGT/PDA 2011 group. These observations sug-
gest that higher two-hour OGTT glucose values can 
be related to increased leukocyte IL6 expression in 
pregnancy because there were more GDM women with 
a two-hour cut-point of 140–153 mg/dL, who shifted from 
the GDM/PDA 2011 group to the NGT/PDA 2014 group 
than NGT women with one-hour cut-point ≥ 180 mg/dL, 
who shifted from the NGT/PDA 2011 group to the 
GDM/PDA 2014 group.
In this study, although statistical analyses failed to 
identify any correlation of leukocyte IL6 mRNAs with 
the clinical parameters of the NGT/PDA 2011 and GDM/ 
/PDA 2011 patients, significant positive linear relation-
ships were observed between leukocyte IL6 expression 
and two-hour post-load glucose concentration in the 
NGT/PDA 2014 and GDM/PDA 2014 groups. Moreover, 
the IL6 mRNA level positively correlated with plasma 
LDL-C concentration and negatively with plasma 
HDL-C concentration in the NGT/PDA 2014 group. 
Nevertheless, there was a significant positive correlation 
of leukocyte IL6 gene expression with two-hour post-
load glucose concentration in the entire study group, 
suggesting that a change of leukocyte IL6 expression 
can be related with a role of IL-6 in regulating blood 
glucose levels during pregnancy. In line with this, 
increased blood glucose after IL-6 infusion in healthy 
individuals [33], as well as a direct stimulatory effect 
of IL-6 on hepatic glucose release from glycogen pools 
by inhibiting glycogen synthase [34], was shown. On 
the other hand, we cannot exclude the possibility that 
high glucose conditions may induce the production of 
greater amounts of IL-6. In this regard, high glucose 
concentration was demonstrated in vitro to induce IL-6 
expression at mRNA and protein levels in monocytes 
through activation of protein kinase C (PKC)-α/β, p38 
mitogen-activated protein kinase (p38 MAPK), and 
nuclear factor-κB (NF-κB) [35]. In addition to glucose 
action, sugar-derived substances called advanced glyca-
tion end products (AGEs) were reported to stimulate 
IL-6 production in human monocytes, implying that 
hyperglycaemia-induced oxidative stress could partici-
pate in these events [36]. Taken together, considerable 
future research will be necessary to establish the cause-
effect relationship between leukocyte IL-6 expression 
and glucose metabolism in the context of pregnancy.
Evidence supports IL-6 as an important inducer of 
CRP expression in hepatocytes by activating the tran-
scription factors STAT3 and CCAAT/enhancer binding 
protein β (C/EBP β) [37–39]. Despite the fact that several 
studies have documented the existence of relationship 
of IL-6 with CRP in GDM women [20, 21], no correla-
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tion was seen between leukocyte IL6 gene expression 
and plasma CRP concentration among GDM patients 
in the present study. This observation is not surprising 
because many molecules, such as IL-1β, IL-4, IL-11, 
TNF-α, and TGF-β, have been shown to be involved 
in regulating CRP expression [40–44].
In summary, our comprehensive comparison of 
clinical characteristics of pregnant women and their 
leukocyte IL6 expression, along with its relationships 
with metabolic parameters of patients, by applying 
the PDA 2011 and 2014 criteria, points to differences 
in metabolic, genetic, and statistical data between the 
GDM groups, identified based on the PDA 2011 and 
2014 criteria, and their respective NGT control groups. 
These differences seem to be highly related to changes 
in gestational glucose tolerance status resulting from us-
ing the PDA 2014 criteria. Importantly, our findings are 
in line with the hypothesis supporting the relationship 
of IL-6 with glucose metabolism during pregnancy, but 
further studies are needed in order to better understand 
the causal pathway that links IL-6 and plasma glucose 
levels in pregnant women.
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